Meet and ask questions to CEO Thomas Warthoe from Qlife on 11 December 2023 at 11.00 AM.

Monday 4 December Qlife Holding announced that its Letter of Intent (LOI) with Hipro Biotechnology, turned into a collaboration agreement. Hipro Biotechnology will sell, distribute, and produce the point-of-care Egoo Health system developed by Olife Holding on the Chinese market, primarily to hospitals of which there are more than 14.000 in China.

Read more about the agreement here: https://www.inderes.dk/analyst-comments/qlife-holding-chinese-partnership-deal-offers-great-potential.

Disclaimer: HC Andersen Capital receives payment from Qlife for a DigitalIR/Corporate Visibility agreement./Claus Thestrup 06/12-2023 10:38 AM/PM.